contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


orion-publishes-interim-report-for-january-september-2022-on-thursday-20-october-2022

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Orion operates in the pharmaceutical industry. The company conducts research and development of human and veterinary drugs, where the main focus is on diseases that affect the nervous system, as well as oncology and respiratory diseases. Today, the company's products are found on a global level, with the largest presence in the Nordic region and the rest of Europe. The company's head office is located in Espoo, Finland.

Orion was covered in Kauppalehti’s Post-Market program.                   Tärkeimmät talousuutiset | Kauppalehti – 7 Dec 25              Jälkipörssi: Cityconin pääomistaja vitkuttelee – Orion-sijoittajat...    Cityconin pääomistaja venytti pakollisen ostotarjouksen aloituksen ensi vuoden puolelle. Jälkipörssi ruotii tällä kertaa Cityconin lisäksi myös Nokian Panimoa ja Orionia.                             There was nothing particularly noteworthy in the comments; only the milestone payment news was commented on in a neutral tone: “In principle, the news was good, although expected by analysts. Reasons for the negative share price reaction can be sought from the fact that the company raised its revenue and operating profit guidance only by the amount of the milestone payment. Most analysts’ revenue forecasts were at the upper end of the new revenue range or above it before the news. The most probable reason is that investors are just too nervous – perhaps now would be a good time to take something to calm down.” Orion is one of the largest direct equity investments in my portfolio (weight approx. 3%), and will remain so for the foreseeable future.

Here are Antti’s comments regarding that recent release.  Orion announced on Wednesday that it would receive a EUR 180 million milestone payment based on the sales of the prostate cancer drug Nubeqa. The milestone payment is the last lump sum related to Nubeqa and will be recorded in the last quarter of 2025. With the confirmation of the payment, the company updated its outlook for 2025. The payment has already been in our forecasts for Q4, so the news does not put pressure on forecast changes.                   Inderes              Orion: viimeinen Nubeqa-etappimaksu varmistui loppuvuodelle - Inderes    Orion saa eturauhassyöpälääke Nubeqan myyntiin perustuvan 180 MEUR:n etappimaksun.

€180M Nubeqa Milestone Payment and Outlook Update: New Outlook Estimate for 2025, issued 3 December 2025 Revenue is estimated to be €1,820–1,900 million.  Operating profit is estimated to be €590–670 million. Previous Outlook Estimate for 2025, issued 28 October 2025 Revenue is estimated to be €1,640–1,720 million.  Operating profit is estimated to be €410–490 million.                   Inderes              Sisäpiiritieto: Orion saa 180 miljoonan euron etappimaksun ja päivittää...    ORION OYJ PÖRSSITIEDOTE – SISÄPIIRITIETO 3.12.2025 KLO 09.00 Sisäpiiritieto: Orion saa 180 miljoonan euron etappimaksun ja päivittää näkymäarviota vuodelle 2025 Orion Oyj on saanut tiedon, jonka...

Orion’s CEO Liisa Hurme was talking about the company’s business at the Investor 2025 event                    Inderes              Orion sijoituskohteena | Sijoittaja 2025 - Inderes    Aika: 28.11.2025 klo 14.16 Orionin toimitusjohtaja Liisa Hurme kertoo yhtiön liiketoiminnasta Sijoittaja 2025 -tapahtumassa.

Right. Strange stock behavior - though the decline seems to have stopped. Bayer, at least, is up about 2%. We await a possible positive profit warning from Orion and hopefully new indications and permission for additional sales next year. At least early-stage prostate cancer (to a layman’s eye) could be a low-hanging fruit,

OP reported that Orion’s partner Bayer released its Q3 report and as part of it, Nubeqa’s product sales. Nubeqa’s Q3 sales were 622 million euros, while Bloomberg’s consensus estimate was 575 million euros. A significant beat of estimates creates upward pressure on Q4/25 and next year’s Nubeqa sales forecasts.

Quite a roast of Orion, worth watching! A couple of scattered observations: -Speculations about selling or spinning off parts of Orion don’t seem to be the primary projects, even though the uniqueness of the veterinary side was highlighted. For example, Mandatum was like a lion caged within Sampo, but it’s hard to see such parts in Orion, and thus the company’s different parts support each other. -Acquisitions are in sight, but targeted ones, and in the order of USA, Japan, Europe. Especially “commercial platform in the USA” was mentioned. -AI primarily speeds up the processing of drug development data, but not as much benefit when progressing to the clinical side. AI disruption in drug sales and distribution is not ruled out. -The USA’s forced reduction of drug prices is comparable to America’s weariness of funding other countries’ defense. When the US market no longer pays for a large part of global drug development, pressure will shift to Europe, and prices will rise here. AstraZeneca’s CEO reiterated the same a few days ago. -In the 10-year vision, Orion’s oncology portfolio, in particular, will be larger than it is now, and products will be sold worldwide. -And the party leader of own shares had to bring up even the grandmother card to get dividends from the days  Perhaps it should be added as a mitigating factor that Orion has de facto lowered its dividend recently, because the increase was below inflation.                   Inderes              ROAST Orion 10.11.2025 - Inderes    Aika: 10.11.2025 klo 14.00 Kieli: fi Orionin toimitusjohtaja Liisa Hurme saapuu Verneri Pulkkisen vieraaksi ROASTiin.

Orion

ORION CORPORATION PRESS RELEASE 6 October 2022 at 9.30 EEST Orion publishes Interim Report for January–September 2022 on Thursday 20 October 2022 Orion will publish Interim Report for January...

ORION CORPORATION PRESS RELEASE 6 October 2022 at 9.30 EEST Orion publishes Interim Report for January–September 2022 on Thursday 20 October 2022 Orion will publish Interim Report for January–September 2022 on Thursday, 20 October 2022 at approximately 12.00 noon EEST. The report and related presentation material will be available on the company’s website at&nbsp;<a href="https://www.globenewswire.com/Tracker?data=xNFWGde3xgstjV9AMhQb2URhj8L91FC_2g6kfj3Q1wJYR0nU9UnhhcITDuuG79KW0ScucZnuQXJckuTGZ_MdzmA7XSxjVD3i3Z69QRW222JK6rL4nWWZ9xy2htIJN5sUgrQGBAsNBWr9j_ZZCRHfbNTL1hbEjqIoU52lknirieJwExHaIlo5M3InzXiRtygSMu_fRvLJkCnz2W8O_xq6W7UNrv8XaC_d9vfnnLh1Y6sbjv-d4CAN8IomeKH1opahlTv2h6RgIF-9Q9jWDGAsCR1mK3O0Cggn2wImD2Q2JiU=">www.orion.fi/en/investors</a>&nbsp;after publishing. Webcast and conference call A webcast and a conference call for analysts, investors and media will be held on Thursday, 20 October 2022 at 13.30 EEST. The event will be held only online and by conference call. A link to the live webcast will be available on Orion's website at&nbsp;<a href="https://www.globenewswire.com/Tracker?data=xNFWGde3xgstjV9AMhQb2URhj8L91FC_2g6kfj3Q1wJAfr9fHrCxo_-rzoOhy9tx_JGeE6bEjeAKAdduon7ScIn-LHlToVN_NhOlJf7S7oUS0e4H5JrR2sUzSYn3kDuGBP_P1yWQxa7kHRoizvmx09YFLJhiGFNPyaev-Q5ZmoN7_fU516A6dWa2VBqfeGbw3CSfGMiSYHnHkWJqA2BoAYjAM349WDmQ1g2uG-U6XFLVurx2xXj4eWe9F65XgmoU31uwPMUKV5LJJyF5FRw4nGeuqMKpwN3kCD4rAg4XVSI=">www.orion.fi/en/investors</a>. A recording of the event will be available on the website later the same day. To participate the conference call, please dial: Finland: +358 9&nbsp;2319 5436 Sweden: +46 8&nbsp;5051 0086 UK: +44&nbsp;33 0551 0211 USA: +1&nbsp;646&nbsp;843 4609 PIN: 8122705# Silent period The silent period preceding the publication is ongoing and continues until the disclosure. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Contact person: Tuukka Hirvonen, Investor Relations, Orion Corporation tel. +358 10&nbsp;426 2721 Publisher: Orion Corporation Communications Orionintie 1A, FI-02200 Espoo, Finland www.orion.fi Orion is a globally operating Finnish pharmaceutical company – a builder of well-being. Orion develops, manufactures and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients. The company is continuously developing new drugs and treatment methods. The core therapy areas of Orion's pharmaceutical R&amp;D are oncology and pain. Orion's net sales in 2021 amounted to EUR 1,041 million and the company had about 3,350 employees at the end of the year. Orion's A and B shares are listed on Nasdaq Helsinki. <img src="https://www.globenewswire.com/newsroom/ti?nf=MTAwMDc0OTM3NCM0MDEzOTcyODkjMjAwMTk2Mw=="> <img src="https://ml-eu.globenewswire.com/media/NWEwNzMxMmYtNjI5Ni00OGQzLThlNjktMWEwZmZkNmEwYjIwLTEwMTM1MzY=/tiny/Orion-Oyj.png">